• Boado RJ, Pardridge WM. 1991. A one-step procedure for isolation of poly A+ mRNA from isolated brain capillaries and endothelial cells in culture. J Neurochem 57: 21362139.
  • Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM. 1999. Selective expression of the large neutral amino acid transporter (LAT) at the blood-brain barrier. Proc Natl Acad Sci USA 96: 1207912084.
  • Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, Sheriff S, Padlan EA, Davies D, Tulip WR, Colman PM, Spinelli S, Alzari PM, Poljak RJ. 1989. Conformations of immunoglobulin hypervariable regions. Nature 342: 877883.
  • Coloma MJ, Lee HJ, Kurihara A, Landaw EM, Boado RJ, Morrison SL, Pardridge WM. 2000. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm Res 17: 266274.
  • Hwang WY, Foote J. 2005. Immunogenicity of engineered antibodies. Methods 36: 310.
  • Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. 1986. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321: 522525.
  • Kabat EA, Wu TT. 1991. Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J Immunol 147: 17091719.
  • Koetzner L, Deng S, Sumpter TL, Weisslitz M, Abner RT, Landry DW, Woods JH. 2001. Titer-dependent antagonism of cocaine following active immunization in rhesus monkeys. J Pharmacol Exp Ther 296: 789796.
  • Lee HJ, Boado RJ, Braasch DA, Corey DR, Pardridge WM. 2002. Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntington's disease with an antisense radiopharmaceutical and drug-targeting technology. J Nucl Med 43: 948956.
  • Li JY, Sugimura K, Boado RJ, Lee HJ, Zhang C, Dubel S, Pardridge WM. 1999. Genetically engineered brain drug delivery vectors: Cloning, expression and in vivo application of an anti-transferrin receptor single chain antibody-streptavidin fusion gene and protein. Protein Eng 12: 787796.
  • Mukherjee J, Christian BT, Narayanan TK, Shi B, Mantil J. 2001. Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Neuropsychopharmacol 25: 476488.
  • Nicholls PJ, Johnson VG, Blanford MD, Andrew SM. 1993. An improved method for generating single-chain antibodies from hybridomas. J Immunol Methods 165: 8191.
  • Pardridge WM. 2001. Brain drug-targeting; The future of brain drug development. United Kingdom: Cambridge University Press. 370 p.
  • Pardridge WM, Eisenberg J, Yang J. 1985. Human blood-brain barrier insulin receptor. J Neurochem 44: 17711778.
  • Pardridge WM, Buciak JL, Friden PM. 1991. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J Pharmacol Exp Ther 259: 6670.
  • Pardridge WM, Kang YS, Buciak JL, Yang J. 1995. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm Res 12: 807816.
  • Wu D, Yang J, Pardridge WM. 1997. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J Clin Invest 100: 18041812.
  • Zhang Y, Schlachetzki F, Pardridge WM. 2003. Global non-viral gene transfer to the primate brain following intravenous administration. Mol Ther 7: 1118.